Rubra Medicaments Limited Unaudited Financial results for the quarter ended on 30th September, 2014

(Figures in Lacs)

Sr. No	Particulars	3 months ended (30/09/2014)	3 months ended (30/06/2014)	3 months ended (30/09/2013)	Year to date figures for current period ended 30.09.2014	Year to date figures for the previous year ended 30.09.2013	Year ended 31st March, 2014
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Net Income from sales /services	0.00	0.00	0.00	0.00	0.00	0.00
2	Cost of sales/services	0.00	0.00	0.00	0.00		0.00
3	Gross Profit (1-2)	0.00	0.00	0.00	0.00		0.00
4	General Administrative Expenses	1.42	2.51	1.04	3.93		5.86
5	Selling and Distribution Expenses	0.00	0.00	0.00	0.00	0.00	0.00
6	Depreciation	0.00		0.00	0.00		0.00
7	Operating Profit before interest (3) – (4+5+6)	-1.42	-2.51	-1.04	-3.93		-5.86
8	Interest	0.00	0.00	0.00	0.00		0.00
9	Exceptional Items	0.00		0.00	0.00		0.00
10	Operating Profit after interest and Exceptional Items (7-8-9)	-1.42	-2.51	-1.04	-3.93		-5.86
	Other Income	0.00	0.00	0.00	0.00	0.00	0.00
12	Profit (+)/Loss (-) from Ordinary Activities before tax (10-11)	-1.42	-2.51	-1.04	-3.93	-2.65	-5.86
	Tax Expense	0.00	0.00	0.00	0.00	0.00	0.00
	Net Profit (+)/ Loss (-) from Ordinary Activities after tax (12-13)	-1.42	-2.51	-1.04	-3.93	-2.65	-5.86
	Extraordinary items (net of tax expense)	0.00		0.00	0.00	0.00	0.00
	Net Profit (+)/Loss(-) for the period(14-15)	-1.42	-2.51	-1.04	-3.93		-5.86
17	Paid-up equity share capital (Face value of the Share is Rs.10/- each)	54683000	54683000	54683000	54683000	54683000	54683000
18	Reserves excluding Revaluation Reserves (as						
	per balance sheet) of previous accounting year	-		-	-	-	-
19	Earnings Per Share (EPS)					_	
	a) Basic and diluted EPS before Extraordinary						
	items for the period, for the year to date and for the previous year (not to be annualized)	-	-	-	-	-	-
	b) Basic and diluted EPS after Extraordinary items for the period, for the year to date and for the previous year (not to be annualized)	-	-	-	-	-	-
20	Public shareholding						
	- Number of shares	5465300	5465300	5465300	5465300	5465300	5465300
L	 Percentage of shareholding 	99.95	99.95	99.95	99.95	99.95	99.95
21	Promoters and promoter group						
	Shareholding **						
	a) Pledged/Encumbered						
	Number of shares	0.00	0.00	0.00	0.00	0.00	0.00
	Percentage of shares (as a % of the total shareholding of promoter and promoter group)	0.00	0.00	0.00	0.00	0.00	0.00
	Percentage of shares (as a% of the total share capital of the company)	0.00	0.00	0.00	0.00	0.00	0.00
	b) Non-encumbered						
	Number of Shares	3000.00	3000.00	3000.00	3000.00	3000.00	3000.00
	Percentage of shares (as a% of the total	100.00	100.00	100.00	100.00	100.00	100.00
	shareholding of promoter and promoter group) Percentage of shares (as a % of the total share		,00.00	.00.00	,00.00		
	capital of the company)	0.05	0.05	0.05	0.05	0.05	0.05

Note:

- 1) The above unaudited results were reviewed by Audit Committee and taken on record by the Board of Directors at its meeting held on 05-11-2014
- 2) Previous Period figures have been regrouped / restated wherever considered necessary.
- 3) There were no Investor's compaint pending at the beginning of the quarter. During the quarter, one investor complaint was received and was resolved. There are no complaint pending at the end of the quarter.

For Rubra Medicaments Limited

Sd/-

Director

Place : Hyderabad

Date: 5th November, 2014.



D. M. Oza & Associates



CHARTERED ACCOUNTANTS

6, Stavan Row Houses, Opp. Heaven Park Society, Ramdevnagar, Satellite, Ahmedabad-380 015. Mobile: 9426014142

E-mail: dmoza04@rediffmail.com

Review Report to:

Rubra Medicaments Limited Hyderabad.

We have reviewed the accompanying statement of unaudited financial results of Rubra Medicaments Limited for the quarter ended 30th September, 2014 except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors/ Committee of Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

For D. M. Oza & Associates

Chartered Accountants

(Proprietor) \
Membership No. 106993

Place : Ahmedabad Date : 05.11.2014